The osteoporosis market in the Asia-Pacific (APAC) region is projected to grow to $7.7bn in 2022, backed by late-stage osteoporosis pipeline comprising anabolic and anti-resorptive therapies, according to a GBI Research report.
Titled ‘Osteoporosis Therapeutics in Asia-Pacific Markets to 2022’, the report states that the APAC market including India, China, Australia, South Korea and Japan will grow at a compound annual growth rate of 7.8% to increase from $4.5bn in 2015.
The late-stage osteoporosis pipeline includes anabolic therapies such as novel sclerostin inhibitors and human parathyroid hormone analogues, and first-in-class anti-resorptive therapies such as cathepsin K inhibitors, which upon launch are expected to lead to dynamic market growth.
Amgen’s Romosozumab (AMG-785) has been identified as a potential winner by the GBI Research report based on its minimal dosage requirement and ability to increase lumbar spine bone mineral density. With its once-monthly dose, the drug is positioned as the second treatment option for patients undergoing anabolic treatment.
The preference for the drug is dependent on its receiving approval before abaloparatide. The target group of Romosozumab will mainly comprise post-menopausal osteoporosis patients.
Major drugs in Japan, such as Forteo and Boniva, are set for patent expiry in 2018 and 2021 respectively along with Viviant and Recalbon / Bonoteo in 2019. The impact of patent expiration of these drugs will be offset by the introduction of drugs that are currently in the pipeline.
The growth in the osteoporosis market will also be supported by an increase in the incidences of osteoporosis, improved diagnostic techniques, and more awareness, dedicated healthcare plans for the elderly, and better insurance coverage.
GBI Research analyst Gayathri Kanika said: “The expansion of health insurance coverage in the APAC region will mean a reduced economic burden on patients, and will provide easier access to healthcare, especially for rural residents.
"As such, the region will see an increase in osteoporosis diagnosis and treatment rates for osteoporosis drugs.”